Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose escalation study of oral LGH447 in Japanese patients with relapsed/refractory hematologic malignancies
jRCT2080222538Phase 1
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PIM447 in multiple myeloma (MM), sponsored by Novartis. Primary endpoints: Safety and tolerability of LGH447 and Maximum tolerated dose (MTD) and/or recommended dose.
02
Drugs
PIM447
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222538.